Thermo Fisher Scientific TMO Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $11.01B— | —— | —— | —— | $10.36B-9.0% | ||
| $336M— | —— | —— | —— | $342M-8.6% | ||
| $2.18B— | —— | —— | —— | $2.08B-5.7% | ||
| $34M— | —— | —— | —— | —— | ||
| $9.14B— | —— | —— | —— | $8.65B-7.8% | ||
| $1.86B— | —— | —— | —— | $1.72B-14.9% | ||
| 16.9%— | —— | —— | —— | 16.6%-1.1pp | ||
| $354M— | —— | —— | —— | $303M-4.4% | ||
| $233M— | —— | —— | —— | $203M-10.6% | ||
| -$8M— | —— | —— | —— | -$14M— | ||
| $1.73B— | —— | —— | —— | $1.62B-16.5% | ||
| $70M— | —— | —— | —— | $95M-36.7% | ||
| $1.65B-15.9% | $1.96B+21.5% | $1.62B-0.1% | $1.62B+7.3% | $1.51B-17.7% | ||
| 15%— | —— | —— | —— | 14.5%-1.5pp | ||
| $5M— | —— | —— | —— | $4M— | ||
| $4.43-15.0% | $5.21+22.0% | $4.27-0.2% | $4.28+7.5% | $3.98-16.7% | ||
| $4.44-14.9% | $5.22+22.0% | $4.280.0% | $4.28+7.3% | $3.99-16.7% | ||
| 373M-1.3% | 378M0.0% | 378M0.0% | 378M-0.3% | 379M-1.0% | ||
| 372M-1.3% | 377M-0.3% | 378M0.0% | 378M0.0% | 378M-1.0% | ||
| $15M— | —— | —— | —— | $98M-67.9% | ||
| $15M— | —— | —— | —— | —— | ||
| $0.01— | —— | —— | —— | —— | ||
| -$88M+37.1% | -$140M-19.7% | -$117M-85.7% | -$63M+53.3% | -$135M+46.9% | ||
| -$150M— | —— | —— | —— | -$43M— | ||
| $0.21— | —— | —— | —— | $0.21— | ||
| $0— | —— | —— | —— | $2M— | ||
| $0— | —— | —— | —— | -$8M— | ||
| -$179M— | —— | —— | —— | -$128M— | ||
| $46M— | —— | —— | —— | $45M— | ||
| $0— | —— | —— | —— | -$28M— | ||
| $83M— | —— | —— | —— | $75M— | ||
| $430M-1.4% | $436M+0.2% | $435M+1.2% | $430M+0.2% | $429M-2.1% | ||
| 3M— | —— | 3M-25.0% | 4M+33.3% | 3M— | ||
| $206M— | —— | —— | —— | $173M— | ||
| -$6.6B— | —— | —— | —— | $132M— | ||
| $0.47— | —— | —— | —— | $0.43— | ||
| $1.6B— | —— | —— | —— | $1.86B— | ||
| -$1M— | —— | —— | —— | $8M— | ||
| $1.6B— | —— | —— | —— | $1.87B— | ||
| -$258M— | —— | -$127M+60.6% | -$322M-15.4% | -$279M-38.1% | ||
| $306M+4.8% | $292M+28.6% | $227M-11.3% | $256M-7.2% | $276M-9.2% | ||
| $175M— | —— | —— | —— | $163M— | ||
| $78M— | —— | —— | $311M+741% | $37M+114% | ||
| $0.04— | —— | —— | —— | $0.06— | ||
| $0.21— | —— | —— | —— | $0.21— | ||
| 0%— | —— | —— | —— | -1.7%— | ||
| $0— | —— | —— | —— | $0— | ||
| $59M— | —— | —— | —— | $19M— | ||
| 3.4%— | —— | —— | —— | 1.2%— | ||
| -8.7%— | —— | —— | —— | -2.6%— | ||
| 0%— | —— | —— | —— | -0.5%— | ||
| $0.01— | —— | —— | —— | $0.01— | ||
| 0%— | —— | —— | —— | -1.7%— | ||
| $14M— | —— | —— | —— | —— | ||
| $0— | —— | —— | —— | -$28M— | ||
| $364M— | —— | —— | —— | $340M— | ||
| -$179M— | —— | —— | —— | -$128M— | ||
| $21M— | —— | —— | —— | $14M— | ||
| $1M— | —— | —— | —— | -$28M— | ||
| $1.11B— | —— | $104M-85.7% | $726M-49.1% | $1.43B— | ||
| 1M— | —— | —— | —— | 1M— | ||
| $1M— | —— | —— | —— | $1M— | ||
| $1.09B-69.0% | $3.53B+658% | -$632M+36.2% | -$991M-872% | -$102M+97.2% | ||
| -$8.96B— | —— | -$4.12B-1,332% | -$288M+45.4% | -$527M— | ||
| $1.19B-65.5% | $3.46B+54.4% | $2.24B+60.0% | $1.4B+93.5% | $723M-78.0% | ||
| $5M— | —— | —— | —— | $4M— | ||
| $4M— | —— | —— | —— | $5M— | ||
| $1.65B— | —— | —— | —— | $1.51B— | ||
| 4— | —— | —— | —— | —— | ||
| -$58M— | —— | —— | —— | $360M— | ||
| -$49M— | —— | —— | —— | $355M— | ||
| -$55M— | —— | —— | —— | $358M— | ||
| -$2M— | —— | —— | —— | $3M— | ||
| $0— | —— | —— | —— | $0— | ||
| $1M— | —— | —— | —— | $1M— | ||
| -$88M+37.1% | -$140M-19.7% | -$117M-85.7% | -$63M+53.3% | -$135M+46.9% | ||
| -$9M— | —— | —— | —— | $3M-78.6% | ||
| $55M+5,600% | -$1M+92.9% | -$14M-100% | -$7M-800% | $1M+133% | ||
| $3B+8,008% | $37M-96.2% | $963M— | $0-100% | $2B+100% | ||
| $37M— | —— | —— | —— | —— | ||
| $162M0.0% | $162M-0.6% | $163M+0.6% | $162M+8.7% | $149M0.0% | ||
| $8.87B— | —— | —— | —— | $0— | ||
| $14M-56.3% | $32M-20.0% | $40M-14.9% | $47M-82.2% | $264M-80.2% | ||
| $376M-19.1% | $465M+15.1% | $404M+37.4% | $294M-18.8% | $362M-24.6% | ||
| $389M— | —— | —— | —— | $0— | ||
| $5.24B+6.5% | $4.92B— | —— | —— | $2.84B— | ||
| $96M+92.0% | $50M-40.5% | $84M+78.7% | $47M-46.0% | $87M+77.6% | ||
| $39M-57.1% | $91M+2,375% | -$4M— | —— | $45M— | ||
| $250M-80.9% | $1.31B— | —— | —— | $2M-99.9% | ||
| $9M-66.7% | $27M+575% | $4M+300% | $1M-91.7% | $12M-29.4% | ||
| $1.41B+79.4% | $787M— | $0-100% | $787M-6.1% | $838M-66.5% | ||
| -$2M— | —— | —— | —— | —— | ||
| $11.01B— | —— | —— | —— | $10.36B-9.0% | ||
| $376M— | —— | —— | —— | $362M— | ||
| $83M-1.2% | $84M+20.0% | $70M-13.6% | $81M+8.0% | $75M-5.1% | ||
| $28M— | —— | —— | —— | $18M— | ||
| $62M— | —— | —— | —— | $65M— | ||
| $44M— | —— | —— | —— | $50M— | ||
| -$6M— | —— | —— | —— | $3M— | ||
| $3B— | —— | —— | —— | $2B— | ||
| $1M— | —— | —— | —— | —— | ||
| $162M0.0% | $162M-0.6% | $163M+0.6% | $162M+8.7% | $149M0.0% | ||
| -$1M— | —— | —— | —— | -$1M— | ||
| -$1M— | —— | —— | —— | $8M— | ||
| $1.6B— | —— | —— | —— | $1.87B— | ||
| -$58M— | —— | —— | —— | $360M— | ||
| -$2M— | —— | —— | —— | $3M— | ||
| -$6M— | —— | —— | —— | $3M— | ||
| $1M— | —— | —— | —— | $1M— | ||
| $0— | —— | —— | —— | $0— | ||
| $0— | —— | —— | —— | $0— | ||
| -$1M— | —— | —— | —— | $1M— | ||
| $2.6B— | —— | —— | —— | $2.42B-12.2% | ||
| 23.6%— | —— | —— | —— | 23.4%-0.8pp | ||
| $1.86B— | —— | —— | —— | $1.72B-14.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Thermo Fisher Scientific's revenue?
- Thermo Fisher Scientific (TMO) generated $43.4B in revenue over the trailing twelve months, up 2.4% year over year.
- Is Thermo Fisher Scientific profitable?
- Thermo Fisher Scientific reported $6.8B in net income over the trailing twelve months, a 15.2% net margin.
- What are Thermo Fisher Scientific's profit margins?
- Gross margin is 58.3% and operating margin is 17.2%, with a 15.2% net margin.
- What is Thermo Fisher Scientific's earnings per share?
- Thermo Fisher Scientific's diluted EPS over the trailing twelve months is $18.19.
- Where does Thermo Fisher Scientific's income statement data come from?
- Every line is extracted from Thermo Fisher Scientific's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
